News - OBI Pharma 台灣浩鼎

2020.May.29

未分類

Corporate

OBI Pharma Posters at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424

2020.May.20

未分類

Corporate

OBI Pharma Announces Poster Presentations at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424

2020.Apr.08

未分類

Corporate

OBI Pharma Updates on Clinical Trial Activities During COVID-19 Pandemic

2020.Jan.21

未分類

Corporate

OBI Pharma Granted U.S. FDA Orphan Drug Designation for the Treatment of Gastric Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999

2020.Jan.09

未分類

Corporate

OBI Pharma, Inc. to Present at the J.P. Morgan Healthcare Conference

2019.Dec.26

未分類

Corporate

OBI Pharma Granted FDA Orphan Drug Designation for the Treatment of Pancreatic Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999

2019.Dec.19

未分類

Corporate

OBI Pharma Announces Initiation of a Phase 1/2 Study of Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999.

2019.Sep.03

未分類

Corporate

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999

2019.Mar.28

未分類

Corporate

OBI Pharma Announces Poster Presentations at AACR 2019 for Novel Globo H Immuno-Oncology Therapeutics: OBI-888 and OBI-999

2019.Feb.12

未分類

Corporate

New Scientific Research provides link between Globo-series glycosphingolipids (GSLs) antigens and tumor survival in Breast Cancer

Announcements

Latest announcements

Events

Latest events